FDA approved anti-cancer drug, nilotinib, increases energy metabolism in astroglia derived from 3xTg mouse model of Alzheimer’s disease.

Benedict Albensi; Aida Adlimoghaddam; R.S. Turner

FDA approved anti-cancer drug, nilotinib, increases energy metabolism in astroglia derived from 3xTg mouse model of Alzheimer’s disease.

Benedict Albensi
, Aida Adlimoghaddam
, R.S. Turner

Department of Pharmaceutical Sciences

Research output: Contribution to conference › Abstract

Original language	American English
State	Published - 2020
Event	21st International Conference Alzheimer’s Drug Discovery Foundation (ADDF) - Virtual Duration: Oct 5 2020 → Oct 6 2020

Conference

Conference	21st International Conference Alzheimer’s Drug Discovery Foundation (ADDF)
Period	10/5/20 → 10/6/20

Cite this

@conference{29bc9ab6fb164079b9aef41574a02c99,

title = "FDA approved anti-cancer drug, nilotinib, increases energy metabolism in astroglia derived from 3xTg mouse model of Alzheimer{\textquoteright}s disease.",

author = "Benedict Albensi and Aida Adlimoghaddam and R.S. Turner",

year = "2020",

language = "American English",

note = "21st International Conference Alzheimer{\textquoteright}s Drug Discovery Foundation (ADDF) ; Conference date: 05-10-2020 Through 06-10-2020",

}

TY - CONF

T1 - FDA approved anti-cancer drug, nilotinib, increases energy metabolism in astroglia derived from 3xTg mouse model of Alzheimer’s disease.

AU - Albensi, Benedict

AU - Adlimoghaddam, Aida

AU - Turner, R.S.

PY - 2020

Y1 - 2020

M3 - Abstract

T2 - 21st International Conference Alzheimer’s Drug Discovery Foundation (ADDF)

Y2 - 5 October 2020 through 6 October 2020

ER -